Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients
Top Cited Papers
Open Access
- 26 March 2013
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Hepatology
- Vol. 58 (5), 1824-1835
- https://doi.org/10.1002/hep.26426
Abstract
Lifelong immunosuppression increases morbidity and mortality in liver transplantation. Discontinuation of immunosuppressive drugs could lessen this burden, but the safety, applicability, and clinical outcomes of this strategy need to be carefully defined. We enrolled 102 stable liver recipients at least 3 years after transplantation in a single‐arm multicenter immunosuppression withdrawal trial. Drugs were gradually discontinued over a 6 to 9‐month period. The primary endpoint was the development of operational tolerance, defined as successful immunosuppressive drug cessation maintained for at least 12 months with stable graft function and no histopathologic evidence of rejection. Out of the 98 recipients evaluated, 57 rejected and 41 successfully discontinued all immunosuppressive drugs. In nontolerant recipients rejection episodes were mild and resolved over 5.6 months (two nontolerant patients still exhibited mild gradually improving cholestasis at the end of follow‐up). In tolerant recipients no progressive clinically significant histological damage was apparent in follow‐up protocol biopsies performed up to 3 years following drug withdrawal. Tolerance was independently associated with time since transplantation (odds ratio [OR] 1.353; P = 0.0001), recipient age (OR 1.073; P = 0.009), and male gender (OR 4.657; P = 0.016). A predictive model incorporating the first two clinical variables identified subgroups of recipients with very high (79%), intermediate (30%‐38%), and very low (0%) likelihood of successful withdrawal. Conclusion: When conducted at late timepoints after transplantation, immunosuppression withdrawal is successful in a high proportion of carefully selected liver recipients. A combination of clinical parameters could be useful to predict the success of this strategy. Additional prospective studies are now needed to confirm these results and to validate clinically applicable diagnostic biomarkers. (Hepatology 2013;58:1824–1835)Keywords
This publication has 35 references indexed in Scilit:
- Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantationJCI Insight, 2012
- The Pattern of Late Mortality in Liver Transplant Recipients in the United KingdomTransplantation, 2011
- Long-Term Follow-Up of 23 Operational Tolerant Liver Transplant RecipientsTransplantation, 2010
- Development of a cross-platform biomarker signature to detect renal transplant tolerance in humansJCI Insight, 2010
- The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: The updated follow up at 78 monthsTransplant Immunology, 2008
- Clinical tolerance following liver transplantation: Long term results and future prospectsTransplant Immunology, 2007
- Chronic Renal Failure after Transplantation of a Nonrenal OrganThe New England Journal of Medicine, 2003
- Skin Cancers after Organ TransplantationThe New England Journal of Medicine, 2003
- Endothelial cell chimerism does not influence allograft tolerance in liver transplant patients after withdrawal of immunosuppression1Transplantation, 2003
- Defining the outcome of immunosuppression withdrawal after liver transplantationJournal of Hepatology, 1998